TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Volume of blood products used
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Immunogenicity of 23vPPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Immunogenicity of TIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vascular inflammation in carotid arterial wall (TBR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: 4 week Continuous Quit Rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Survival without major clinical event
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of patients with colorectal neoplastic lesions detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in standardized uptake value (SUV) uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of discordance and concordance between gallium Ga 68-edotreotide and biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montgomery and Asberg Depression Rating Scale (MADRS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Working Memory Capacity
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in community-wide oropharyngeal Hib colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Times of C-arm fluoroscopy used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Area Under the Concentration-time Curve (AUC) From the Time of Dosing Extrapolated to Time Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative knee function assessed by clinical examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative knee function assessed by scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Recombinant Human Interleukin-15 (rhIL-15)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grades 3, 4 or 5 Dose-Limiting Toxicity (DLT) Related to Study Drug
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in anti glaucoma medications
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Clinical and laboratory adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of persons who develop atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of liver functions as assessed by MELD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events as assessed according to CTCAE 4.03
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Serious and Non-Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Best Corrected Distance Visual Acuity (BCDVA) (ETDRS Chart)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain intensity rating differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atherogenic lipoproteins levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: response to treatments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Severity of ADHD Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative numbers and diameters of colorectal adenomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Columbia-Suicide Severity Rating Scale (C-SSRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Understanding of information
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall improvement in knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Insomnia Severity Index (ISI)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in right ventricle end diastolic area (EDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in tricuspid annular plane systolic excursion (TAPSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in ratio between early mitral inflow velocity and mitral annular early diastolic velocity (E/e')
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency spectrum of basal ganglia local field potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Yearly Rebleeding Times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body mass index (kg/m2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Usability of headset application
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cmax after administration of CKD-828
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: CTCAE Grade 3 or 4 Gastro-intestinal (GI) Toxicities or Death Within 90 Days From the Start of Therapy
Endpoint domain: Adverse events/effects
Primary endpoint: Radiographic Stable Disease (SD) or Better Based on RECIST Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Prognostic value of biomarkers in bacteremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in force-velocity characteristics of knee extensors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Accuracy of endoscopists for interpretation of cytologic specimen adequacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary diagnosis of malignancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Composite incidence of recurrent symptomatic ischaemic stroke, symptomatic intracranial haemorrhage and systemic embolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of genetically ascertained patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Successful Intubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Pulmonary Artery Pressure (PAPmean)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osmolality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma PK assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Forward movement along the HCV care continuum
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change From Baseline on the Numeric Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate after induction therapy
Endpoint domain: Mortality/survival
Primary endpoint: Rate of plasma urea reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: BG concentration differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-∞) of Unchanged MT-6548
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Plasma Concentration (Cmax) of Unchanged MT-6548
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Reach Maximum Plasma Concentration (Tmax) of Unchanged MT-6548
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood culture contamination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Serological identification of SARS-CoV-2 infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration-time profile of Oral Paclitaxel in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: External fixation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incontinence Status as Assessed by Stamey Grade Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With One Point Improvement in Stamey Grade Scores up to Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Weekly Hemoglobin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Weekly Dosage of Study Medication
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Macular Pigment Optical Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Serious Adverse Drug Reactions (SADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Unexpected Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Unexpected ADRs
Endpoint domain: Adverse events/effects
Primary endpoint: Positive conversion rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of Ratio of total cholesterol to HDL cholesterol (TC:HDL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Development of acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Number of Dose-Limiting Toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Depression Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total patients who achieved sustained and overall response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral Atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: White matter fractional anisotropy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain network connectivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent of mothers screening positive for maternal depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 6-Month Closure Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6-Month Composite Clinical Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Confirmed Best Overall Response Rate (BORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in pain levels
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: change in anxiety levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composition of Microorganisms in stool
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximum target to background ratio (TBRmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in nutritional knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Duration Without Large Deviation of End-Tidal Anesthetic Agent (EtAA) Based on Extraction Algorithm (ALG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Duration Without Large Deviation of End-Tidal Anesthetic Agent (EtAA) Based on Clinician's or Investigators' Recorded Target Values of Anesthetic Agent and Oxygen (TGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Duration Without Large Deviation of End-Tidal Oxygen (EtO2) Based on Extraction Algorithm (ALG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Duration Without Large Deviation of End-Tidal Oxygen (EtO2) Based on Clinician's or Investigators' Recorded Target Values of Anesthetic Agent and Oxygen (TGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autism Diagnostic Observation Schedule
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical anomalies and craniofacial features
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain structural anatomy with MRI scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood magnesium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urine magnesium concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean reduction in anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hollunder cosmetic score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disease free survival rate (DFS)
Endpoint domain: Mortality/survival
Primary endpoint: Change From Baseline on the Symbol Digit Modalities Test (SDMT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Timed 25-foot Walk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Physical functioning
Primary endpoint: Change From Baseline on the Paced Auditory Serial Addition Test (PASAT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline on the Brief Visuospatial Memory Test-Revised (BVMT-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline on the California Verbal Learning Test, Second Edition (CVLT-II)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Stroke prevalence
Endpoint domain: Mortality/survival
Primary endpoint: Modified Rankin Scale (MRS) score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects with a good histological tumour response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants That Experience Grade 2-4 Acute GVHD
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of Cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Altered Mental Status Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Visual Analog Scale Pain Score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Change in Serum Total Catecholamines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Housing Security Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Housing Security Scale (Subjective Housing Stability Subscale)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in neutrophils/mm in ascitic fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in IL-6, IL-1, TNF in ascitic fluid and serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Successful Segmentation of Supine MRI Images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Disease Progression or Death
Endpoint domain: Mortality/survival
Primary endpoint: Correlation between pathologic response for ES, RMS and STS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Drug-related Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical improvement of signs and symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amplification or new development of NY-ESO-1, MAGE-A1, or MAGE-A3 specific T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum Lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Non Administration of Prescribed VTE Prophylaxis Medication Doses
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in gastrointestinal tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median pO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HP5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: eHealth Literacy Questionnaire scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptance of eHealth care scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health Technology Usage Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient Health Engagement score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breath gas markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Experience following the disclosure of incidental findings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perception and expectations regarding the way results are given
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Repercussions of access to incidental findings
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Tear cytokines change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Functional Capacity - Six-Minute Walk Test (6MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of SVF and aaPRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of SVF and aaPRP
Endpoint domain: Adverse events/effects
Primary endpoint: Serum predictors of response to immune checkpoint inhibitors at study entry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum predictors of response to immune checkpoint inhibitors 4-weeks after initiation of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum predictors of response to immune checkpoint inhibitors anytime between 6-12 weeks after initiating treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: pain score at discharge from Post-Anesthesia Care Unit (PACU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain Visual Analog Scale (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Length of Stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Turesky plaque index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Histopathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose
Endpoint domain: Adverse events/effects
Endpoint subdomain: Any subdomain
Primary endpoint: Composite of hemodynamic parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stroke Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of capsular contracture (grade 3 or higher) by Baker's scale
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of capsular contracture (grade 3 or higher) by 2D shear elastography
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Times Cocaine Was Selected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of GALNT4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal COVID-19 serology (IgG and IgM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maternal/neonatal IgG and IgM concordance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maternal COVID serology time/profile following vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Breastmilk Serology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to EGFR-TKI failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serologic response to MMR vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Success rate of rate control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Silness Gingival index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of virological response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes